PHARMAHUNGARY 2000 KISERLETES ES KLINIKAI KUTATASFEJLESZTESI KORLATOLTFELELOSSEGU TARSASAG

Their core work

PharmHungary is a Szeged-based pharmaceutical R&D company specializing in experimental and clinical research, with a strong focus on cardiovascular diagnostics and biomarker development. They develop diagnostic tools for acute cardiac conditions and have expanded into AI-driven prognostic models for infectious diseases. Their work bridges preclinical pharmacology research with in-vitro diagnostic (IVD) product development, positioning them at the intersection of drug research and clinical decision support.

What they specialise in

How they've shifted over time

PharmHungary began with a focused bet on cardiac diagnostics — their 2015 Infarnosys project (which they coordinated) aimed to build a biomarker system for heart attack prognosis. By 2020-2021, they diversified into AI-driven prognostic tools and expanded from cardiology into infectious disease (COVID-19) and neuroscience/ophthalmology (CRYSTAL3). The shift suggests a company moving from single-disease diagnostics toward broader biomarker-based precision medicine, increasingly incorporating computational methods.

PharmHungary is evolving from a cardiac diagnostics specialist toward a broader biomarker and AI-prediction company, making them relevant for any consortium needing preclinical-to-clinical translation with computational elements.

How they like to work

PharmHungary has operated as both a coordinator (Infarnosys, an SME Phase 1 project they led independently) and a contributing partner in larger consortia (COVIRNA, CRYSTAL3). With 29 unique partners across 15 countries from just 3 projects, they are comfortable operating in wide international networks. Their mix of an SME instrument grant and participation in MSCA-RISE and Innovation Action projects suggests they are adaptable — capable of driving their own R&D agenda while also fitting into larger collaborative frameworks.

Despite only three projects, PharmHungary has built a remarkably wide network of 29 partners spanning 15 countries, largely through the multi-partner COVIRNA and CRYSTAL3 consortia. Their reach extends well beyond Central Europe into a broad European and possibly global network.

What sets them apart

PharmHungary combines hands-on experimental pharmacology (their name literally translates to "Experimental and Clinical R&D") with growing computational capabilities in biomarker prediction. For a Hungarian SME, their breadth of international collaboration is unusually wide. They offer consortium builders a rare profile: a small, agile company that can contribute both wet-lab biomarker expertise and data-driven patient stratification, without the overhead of a large institution.

Highlights from their portfolio

• Infarnosys
  Their first and only coordinated project — an SME Phase 1 feasibility study for a cardiac biomarker diagnostic system, signalling their core commercial ambition.
• COVIRNA
  A timely pivot applying their cardiovascular biomarker expertise to COVID-19 prognosis using AI and long non-coding RNA — demonstrates adaptability and relevance to pandemic preparedness.